Navigation Links
Trianni Announces Launch of Its Optimized Human Antibody Transgenic Mouse
Date:9/26/2013

ge arrays, which were then embedded in the mouse genome in place of their normal mouse counterparts.  The outcome was antibody genes that are optimized for function in the mouse yet nonetheless express a full repertoire of human variable domains.  The Trianni mouse that carries these unique genes is a validated platform ideal for the isolation of therapeutic monoclonal antibodies.

About Trianni

Trianni was formed in 2010 with the sole focus of developing and distributing its optimized antibody discovery platform, The Trianni Mouse. It has been funded throughout from private sources. The company has administrative and research facilities in the San Francisco Bay Area and in Germany, respectively. Its executive team includes academic molecular immunologists and business development personnel with successful track records in biotechnology.

Contact:

Michael Greenberg, Chief Business Officer
Phone: +1 650-530-0640
Email: Michael.greenberg@trianni.com

 


'/>"/>
SOURCE Trianni
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 The Pharmaceutical Care Management ... managers (PBMs), today filed a lawsuit in ... Iowa law that restricts tools ... the state,s employers and consumers.  The ... severely restricting the use of Maximum Allowable Cost (MAC) ...
(Date:9/2/2014)... Spanien und CALGARY, Alberta , September ... Vorgestellt in der "State of the Art and Featured ... Resverlogix Corp. (TSX: RVX) gab heute bekannt, ... bei Resverlogix, beim Kongress des europäischen Kardiologenverbandes (ESC) 2014 ... gehalten hat. In seinem Vortrag mit dem Titel " ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
Breaking Medicine Technology:Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
... June 26, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... LLY ) today announced results from a ... BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall ... that produce insulin.) Three years of BYETTA therapy improved ...
... June 25 Novo Nordisk today presented phase 2 ... which demonstrated the potential to help achieve target glycemic control when ... at the 70th Scientific Sessions of the American Diabetes Association (ADA).(1) ... These ...
Cached Medicine Technology:Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 2Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 3Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 4Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 5Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 6Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 7Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 8Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week 2Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week 3
(Date:9/2/2014)... the groundwork for their own spread throughout the body ... tumor-welcoming signals, according to a new report by Johns ... of Nature Communications , the researchers describe animal ... signaling molecules released by breast cancer cells. These molecules ... lymph nodes to produce proteins called CCL5 and VEGF. ...
(Date:9/2/2014)... Melbourne, Australia (PRWEB) September 03, 2014 ... Australia attend to millions of people annually, arranging care ... subdivision's not-for-profit and private enterprises are expected to derive ... government funding, donations and private income. Over the five ... at an annualised rate of 6.6%, including growth of ...
(Date:9/2/2014)... 2014 (HealthDay News) -- Melatonin supplements did not reduce ... a new study found. Many older hospital patients ... to disruption of their normal sleep-wake cycle. A lack ... contributes to delirium, but there has been little research ... This study included 378 patients, average age 84, who ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... the Ebola outbreak continues to overwhelm health-care workers in ... States and the United Nations called on Tuesday for ... of the often-fatal virus. Dr. Thomas Frieden, director ... said that without a greater global commitment in resources ...
(Date:9/2/2014)... Albany, New York (PRWEB) September 02, 2014 ... lucrative business with products and services such as ... color, radio frequency-device based treatments, and breast augmentation ... market report published by U.S.-based market intelligence firm ... anti-aging treatments and products will grow to USD ...
Breaking Medicine News(10 mins):Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3
... now has nearly 400 million hectares of natural grassland, the ... its usable grassland has degraded to various extents and hence ... efforts to protect the country's grasslands. ,He said ... sustainable economic growth. , This is mainly done ...
... As a normal charge contraceptives have a VAT of 17.5% ... and other contraceptives in the ensuing budget.,Gordon Brown is due ... said by High Street chemist Superdrug which said that it ... to 5%. It said the move followed a successful 10-month ...
... - The radiation watchdog in Finland has decided to test ... human proteins by testing them directly on human skin in ... health.// ,A pilot study that is scheduled to ... skin on the participants' arms to cell phone radiation for ...
... product of rice processing, called rice bran, significantly lowers ... humans.// ,Journal of Agricultural and Food Chemistry, ... scientific society holds the nuances of the study. ... Brewing researchers’ showed that if rice ran is added ...
... motivator has been helping South Africans to improve their lives ... workshops in various cities seek to teach// people how to ... says lies between the conscious state and sleep. ... 10 percent of their mind power," Adhia told students at ...
... reported that women in India are gradually becoming more ... 40 percent of India’s infected population//. ,"Women ... disparities, lack of education and trafficking of women are ... the women's human rights and human security unit, United ...
Cached Medicine News:Health News:Biologically Women Are More Vulnerable To HIV Infection 2
Used to introduce large devices for vascular intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established.,NOTE: Use of a heavy-duty wire guide is recommended....
Portless Sheath Introducers...
Medicine Products: